BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18086799)

  • 41. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N; Al-Diab AI
    Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
    Montalbán C; García JF; Abraira V; González-Camacho L; Morente MM; Bello JL; Conde E; Cruz MA; García-Sanz R; García-Laraña J; Grande C; Llanos M; Martínez R; Flores E; Méndez M; Ponderós C; Rayón C; Sánchez-Godoy P; Zamora J; Piris MA;
    J Clin Oncol; 2004 May; 22(9):1664-73. PubMed ID: 15117989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignant lymphomas in the elderly: a single institute experience highlights future directions.
    Váróczy L; Dankó A; Simon Z; Gergely L; Ress Z; Illés A
    Arch Gerontol Geriatr; 2007; 45(1):43-53. PubMed ID: 17079031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-line treatment of Hodgkin's lymphoma.
    Klimm B; Engert A; Diehl V
    Curr Hematol Rep; 2005 Jan; 4(1):15-22. PubMed ID: 15610655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Skeletal involvement in Hodgkin's lymphoma--personal experience].
    Feltl D; Marková J; Kozák T
    Vnitr Lek; 2004 Feb; 50(2):134-8. PubMed ID: 15077588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
    Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
    Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
    Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD
    Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.
    Martini M; Hohaus S; Petrucci G; Cenci T; Pierconti F; Massini G; Teofili L; Leone G; Larocca LM
    Am J Clin Pathol; 2008 Mar; 129(3):472-7. PubMed ID: 18285272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
    Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
    Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].
    Bence Z; Kovács G; Jakab Z; Csóka M; Müller J
    Magy Onkol; 2008 Dec; 52(4):357-62. PubMed ID: 19068463
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages].
    Raida L; Papajík T; Indrák K; Herman M; Paucek B; Zapletalová J
    Vnitr Lek; 2007 Jan; 53(1):31-7. PubMed ID: 17472013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
    Bröckelmann PJ; Goergen H; Kohnhorst C; von Tresckow B; Moccia A; Markova J; Meissner J; Kerkhoff A; Ludwig WD; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2017 May; 35(13):1444-1450. PubMed ID: 28240973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-Hodgkin's lymphoma of Waldeyer's ring in children: outcome using chemotherapy and involved field radiotherapy.
    Laskar S; Bahl G; Muckaden MA; Pai S; Nair R; Gupta S; Shet T; Gujral S; Arora B; Sengar M; Shrivastava SK; Dinshaw KA
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):613-8. PubMed ID: 18585015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
    Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.